Physician profile
Ke Yang
NPI 1316438328
$876.69
in general payments reported to CMS, 2019-2025
13 companies · $85.46 in 2025
The $85.46 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $276 · 2024: $315 · 2025: $85.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $98.71 | 2022-2025 | |
| Lilly USA, LLC | $92.67 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $71.17 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $54.05 | 2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $45.14 | 2024 | Spravato |
| Eisai INC. | $43.24 | 2023 | |
| Pfizer INC. | $37.25 | 2022-2024 | |
| Exact Sciences Corporation | $36.35 | 2023 | Cologuard Collection Kit |
| Organon LLC | $34.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.89 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $26.06 | 2023 | Shingrix |
| Sonex Health, INC. | $15.74 | 2023 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ke Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.